Accessibility Menu
Akebia Therapeutics logo

Akebia Therapeutics(NASDAQ) AKBA

Market Cap$249.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-97%
5 Year-66%
1 Year-72%
1 Month-26%
Premium Feature
Moneyball Superscore
50/100
$0.90
-0.88%
-0.01Today
After hours$0.90+$0.00 (+0.05%)
Akebia Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.902026-08-24
Akebia Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.72%USD 0.862026-08-17
1 month-26.18%USD 1.222026-07-24
3 month-13.4%USD 1.042026-05-26
Year to date-44.06%USD 1.612025-12-31
1 year-71.77%USD 3.192025-08-22
3 year-21.69%USD 1.152023-08-25
5 year-66.4%USD 2.682021-08-25
Since inception-96.6%USD 26.702014-03-20

Akebia Therapeutics Financials at a Glance

Market Cap

$249.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$219.06M

Net Income (TTM)

-$29.67M

EPS (TTM)

-$0.11

P/E Ratio

-8.11

Dividend

$0.00

Beta (Volatility)

1.54 (High)

Price

$0.90

Volume

110.99

Open

$0.91

Previous Close

$0.90

Daily Range

$0.87 - $0.91

52-Week Range

$0.81 - $3.22

Estimated Earnings Date

Nov 9, 2026

AKBA News

Foolcom-Featured.png

Akebia (AKBA) Q2 Revenue Jumps 43%

Motley Fool Markets TeamAug 7, 2025
Physician monitoring patients onscreen vitals

Why Shares of Akebia Therapeutics Were Up Tuesday

James HalleyMay 23, 2023
Dialysis

Why Akebia Therapeutics Stock Is Soaring Today

Keith SpeightsAug 5, 2021
GettyImages-521072395

Why Akebia Therapeutics Stock Is Plunging Today

Prosper Junior BakinyFeb 25, 2021
Man looking at line chart going through floor

Why Akebia Therapeutics Stock Is Crashing Today

Keith SpeightsSep 3, 2020
Anemia on small whiteboard

Why Akebia Therapeutics Stock Is Crushing It Today

Keith SpeightsMay 5, 2020
high growth (2)

2 Small-Cap Stocks That Could Double Your Money

George Budwell, PhDApr 18, 2020
Black and white of two test tubes

Why Akebia Therapeutics Stock Sank Today

Keith SpeightsMar 10, 2020
Page 1

AKBA: Motley Fool Moneyball Superscore

50

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akebia Therapeutics

Akebia Therapeutics makes medicines for people with kidney disease. These drugs help patients manage blood issues like anemia. The company also treats high mineral levels in the blood.

Addressing Chronic Kidney Conditions

  • Vafseo: Orally administered hypoxia inducible factor (HIF) based treatment for anemia in adult dialysis patients; generated $21.3 million in revenue in the second quarter of 2026. HIF is a protein that helps the body produce red blood cells.
  • Auryxia: Ferric citrate tablets used to control serum phosphorus levels in dialysis patients and treat iron deficiency anemia; generated $25.5 million in revenue in the second quarter of 2026.
  • License and Collaboration: Revenue generated from agreements with international partners for the development and supply of drug products.

Recent Strategic Steps

  • Purchased ebribafusp from Q32 Bio in November 2025 to target rare kidney diseases like IgA Nephropathy, which causes kidney inflammation.
  • Licensed praliciguat from Cyclerion Therapeutics in June 2021 to treat rare kidney conditions that damage the organ's filters.
  • Launched Vafseo in the United States in January 2025 after receiving FDA approval in March 2024.
  • Initiated a Phase 2 basket study in August 2026 to test ebribafusp across multiple rare kidney diseases.
  • Reduced the workforce by 13% in June 2026 to increase the efficiency of the commercial field team.

How the Company Stands Out

Akebia manages the entire process of finding, developing, and selling its kidney treatments. The company also maintains a global presence with products approved for use in 37 countries.

Tracking the Financial Results

  • Net product revenue was $46.8 million for the three months ended June 30, 2026, down 23% year over year.
  • Vafseo revenue increased to $21.3 million in the second quarter of 2026, up from $13.3 million year over year.
  • The company recorded a net loss of $18.0 million for the six-month period ended June 30, 2026.
  • Cash and cash equivalents totaled $155.5 million as of June 30, 2026.

Evolution of the Business

Akebia is transitioning its business from its legacy iron-based brand to the launch of Vafseo and a new pipeline of rare disease treatments. The company continues to manage the market entry of generic competition while advancing its mid-stage clinical programs.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

194

CEO

John P. Butler, MBA

Website

www.akebia.com

Headquarters

Cambridge, MA 02142, US

AKBA Financials

Key Financial Metrics (TTM)

Gross Margin

79.48%

Operating Margin

-6.91%

Net Income Margin

-13.54%

Return on Equity

-93.74%

Return on Capital

9.44%

Return on Assets

-8.48%

Earnings Yield

-12.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$249.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

277.11M

Volume

110.99

Avg. Volume

5.06M

Financials (TTM)

Gross Profit

$174.10M

Operating Income

-$15.13M

EBITDA

-$18.01M

Operating Cash Flow

$41.55M

Capital Expenditure

-$1.38M

Free Cash Flow

$40.23M

Cash & ST Invst.

$155.55M

Total Debt

$53.96M

Akebia Therapeutics Performance Analysis

Akebia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 292,484,00038.2%
20232023-12-31USD 194,623,000-33.5%
20242024-12-31USD 160,180,000-17.7%
20252025-12-31USD 236,196,00047.5%
Akebia Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.9%
Q42025-12-31-2.0%
Q12026-03-31-7.1%
Q22026-06-30-8.2%
Akebia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.52-69.7%
20232023-12-31USD -0.28-46.3%
20242024-12-31USD -0.3318.8%
20252025-12-31USD -0.02-93.7%
Akebia Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30122.2%
Q42025-12-31-2405.0%
Q12026-03-3126.5%
Q22026-06-3011.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$49.13M

-21.4%

Gross Profit

$38.70M

-26.4%

Gross Margin

78.78%

N/A

Market Cap

$249.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.29M

N/A

Employees

194

N/A

Net Income

-$8.91M

-3706.5%

EBITDA

-$4.85M

-165.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$155.55M

+13.3%

Total Debt

$53.96M

+1.1%

Accounts Receivable

$53.51M

-26.5%

Inventory

$13.02M

-22.1%

Long Term Debt

$29.15M

-38.9%

Short Term Debt

$24.81M

+340.7%

Return on Assets

-8.48%

N/A

Return on Invested Capital

-8.01%

N/A

Free Cash Flow

$2.45M

-89.0%

Operating Cash Flow

$3.53M

-84.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GOSSGossamer Bio, Inc.
$0.18+13.12%
CMPXCompass Therapeutics, Inc.
$2.40+0.00%
PRTAProthena Corporation plc
$9.39-0.63%
ZVRAZevra Therapeutics, Inc.
$11.65-1.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.16-0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$50.75+0.08%
IBITiShares Bitcoin Trust
$44.64+0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.19+0.03%

Questions About AKBA

What is the current price of Akebia Therapeutics?

Akebia Therapeutics is trading at $0.90 per share.

What is the 52-week range for Akebia Therapeutics?

Over the past 52 weeks, Akebia Therapeutics has traded between $0.81 and $3.22.

How much debt does Akebia Therapeutics have?

As of the most recent reporting period, Akebia Therapeutics reported total debt of $210.81M.

How much cash does Akebia Therapeutics have on hand?

Akebia Therapeutics reported $157.26M in cash and cash equivalents in its most recent financial results.

What is Akebia Therapeutics’s dividend yield?

Akebia Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services